Dr. Somaiah on NY-ESO-1 Expression in Soft Tissue Sarcoma

Neeta Somaiah, MD
Published: Thursday, Jul 06, 2017



Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the expression of NY-ESO-1 in patients with soft tissue sarcoma.

There were previous studies looking at the NY-ESO-1 expression across different sarcoma subtypes, explains Somaiah. However, the percentage of NY-ESO-1 expression in those other subtypes is around 30% whereas it is around 80% to 100% for soft tissue sarcoma.
 


Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the expression of NY-ESO-1 in patients with soft tissue sarcoma.

There were previous studies looking at the NY-ESO-1 expression across different sarcoma subtypes, explains Somaiah. However, the percentage of NY-ESO-1 expression in those other subtypes is around 30% whereas it is around 80% to 100% for soft tissue sarcoma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x